Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease
This case demonstrates the potential for continued radiographic and clinical improvement in TED patients after retreatment with teprotumumab. Further studies may clarify the role of EOM volume as a marker for treatment efficacy.
Authors
- Marissa K. Shoji (ORCID: https://orcid.org/0000-0002-6297-4674)
- David B. Granet (ORCID: https://orcid.org/0000-0001-8011-2480)
- Megan R. Routzong (ORCID: https://orcid.org/0000-0001-5551-1156)
- Jolene C. Rudell (ORCID: https://orcid.org/0000-0003-3022-4649)
- Don O. Kikkawa
- Hanna Richkind (ORCID: https://orcid.org/0009-0009-6728-4398)
Institutions
- Fleet Science Center (US)
- Sanford Consortium for Regenerative Medicine (US)
- The California Eye Institute (US)
Publication Details
- Journal
- American Journal of Ophthalmology Case Reports
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.ajoc.2025.102490
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00